Aberdeen Group plc Acquires 185,245 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc boosted its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 46.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 586,869 shares of the company’s stock after buying an additional 185,245 shares during the period. Aberdeen Group plc’s holdings in Structure Therapeutics were worth $16,432,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. State of Wyoming purchased a new position in shares of Structure Therapeutics during the second quarter valued at about $28,000. Assetmark Inc. boosted its stake in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Structure Therapeutics in the 2nd quarter worth approximately $129,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Structure Therapeutics during the 2nd quarter worth approximately $221,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on GPCR. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Stifel Nicolaus lifted their price target on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, HC Wainwright upped their price objective on Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.20.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $68.36 on Thursday. The company has a market cap of $4.15 billion, a P/E ratio of -56.03 and a beta of -2.06. The firm has a 50-day simple moving average of $75.09 and a two-hundred day simple moving average of $44.32. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $13.22 and a 1 year high of $94.90.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.